People are already putting cagri together with sema, reta, and tirz in single vials. My bet is the same will happen with elora once production settles down. Probably in about six months.
Curious if anyone knows the science here. There's talk of running trials combining eloralintide with tirzepatide or retatrutide, which sounds promising and a lot of people want to try it. The question is whether the more complex manufacturing makes it realistic to put both in one solution. One company dropped their own co-formulation project, possibly because keeping them separate is simpler and cheaper.